Torsemide
Brand names: Demadex (US, generic); Soaanz (US, extended-release; Sarfez Pharmaceuticals)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Edema associated with heart failure | Adults | Monotherapy or combination diuretic regimens | FDA Approved |
| Edema associated with renal disease | Adults | Monotherapy; higher doses often required | FDA Approved |
| Edema associated with hepatic disease (Demadex/generic only — not Soaanz) | Adults | Per FDA label, must be combined with an aldosterone antagonist or potassium-sparing diuretic | FDA Approved (Demadex) |
| Hypertension (Demadex/generic only — not Soaanz) — to lower BP and reduce risk of fatal and non-fatal CV events | Adults | Monotherapy or combination antihypertensive therapy | FDA Approved (Demadex) |
Torsemide is one of three loop diuretics in routine US clinical practice — alongside furosemide and bumetanide — but stands apart from the other two in two important ways. It is the only US-marketed loop diuretic without a boxed warning in the current prescribing information, and the only loop diuretic that is not chemically a sulfonamide (it is a pyridine-sulfonylurea). It shares an FDA-approved hypertension indication with furosemide; bumetanide is not FDA-approved for hypertension. The 2022 ACC/AHA/HFSA Heart Failure Guideline endorses loop diuretics — including torsemide — as Class 1, Level B-NR therapy in heart failure patients with congestion or fluid retention.
The principal pharmacologic advantages of torsemide over furosemide are reproducible bioavailability of approximately 80% per the FDA label, a longer elimination half-life of ~3.5 hours that affords a more sustained natriuretic profile (6–8 h duration), and unchanged total plasma clearance in renal impairment because hepatic metabolism compensates. The largest pragmatic head-to-head trial — TRANSFORM-HF (Mentz, JAMA 2023) — found no difference in 12-month all-cause mortality between torsemide and furosemide after a heart-failure hospitalization, prompting many clinicians to base loop-diuretic choice on tolerability, cost, and absorption reliability rather than presumed mortality benefit.
Note that the FDA-approved indications differ between formulations: standard torsemide tablets (Demadex/generic) and IV injection are approved for edema associated with HF, renal disease, or hepatic disease, and for hypertension. The Soaanz extended-release formulation (approved June 2021) is approved only for edema associated with heart failure or renal disease — it is not approved for hepatic disease edema or for hypertension.
Acute decompensated heart failure — IV bolus or continuous infusion in hospitalized patients; the DOSE-trial framework (Felker, NEJM 2011) developed for furosemide is generally extrapolated to torsemide. (Evidence: moderate)
Refractory ascites in cirrhosis — combined with spironolactone in stepwise fashion. (Evidence: moderate)
Diuretic-resistant fluid overload — switching from furosemide to torsemide is widely practised when oral furosemide absorption is unreliable. (Evidence: moderate)
Pediatric edema — limited published experience; FDA labelling explicitly states safety and efficacy in pediatric patients have not been established. (Evidence: limited)
Hypercalcemia — adjunctive after volume repletion with isotonic saline. (Evidence: low)
Dosing
Torsemide dosing is titrated to clinical response. Per the FDA label, the recommended titration strategy is to double the dose at intervals until adequate diuresis is achieved. The label provides upper-bound guidance — doses above 200 mg/day in heart failure and CKD, and above 40 mg/day in cirrhosis, have not been adequately studied. Because oral bioavailability is approximately 80% per the FDA label, oral and IV doses are therapeutically equivalent, allowing seamless conversion between routes.
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Edema associated with heart failure (oral or IV) | 10 mg or 20 mg PO/IV once daily | Titrate by approximately doubling until desired response is achieved | Per FDA label, doses above 200 mg/day have not been adequately studied | Once-daily dosing is feasible because of the 6–8 h duration. In decompensated HF, total clearance is approximately 50% of normal per FDA label, so AUC and plasma half-life are correspondingly increased Take in the morning to avoid nocturia; second daily dose, if needed off-label, in early afternoon |
| Edema associated with chronic renal failure | 20 mg PO once daily | Titrate by approximately doubling until desired response is achieved | Per FDA label, doses above 200 mg/day have not been adequately studied | In renal failure, total plasma clearance and t½ remain normal because hepatic metabolism is preserved per the FDA label, but a smaller fraction of each dose reaches the tubular site of action — hence the higher starting dose |
| Edema associated with hepatic cirrhosis (Demadex/generic only) | 5 mg or 10 mg PO once daily together with an aldosterone antagonist or potassium-sparing diuretic | Titrate by approximately doubling until desired response is achieved | Per FDA label, doses above 40 mg/day have not been adequately studied in this population | Per FDA label, initiate diuresis in the hospital because sudden electrolyte shifts may precipitate hepatic encephalopathy. Vd is approximately doubled in cirrhosis Concurrent aldosterone antagonist is required, not just suggested, per FDA labelling |
| Hypertension — initial therapy (Demadex/generic only) | 5 mg PO once daily | If 5 mg is inadequate after 4–6 weeks, increase to 10 mg PO once daily | If 10 mg is insufficient, add another antihypertensive agent rather than increasing further per FDA label | The antihypertensive effect approaches maximum at 4–6 weeks and may continue to increase for up to 12 weeks per FDA label. BP-lowering effect is, on average, greater in Black patients Mean potassium decrease at 5–10 mg is only ~0.1 mEq/L per FDA PI |
| IV continuous infusion (off-label, ADHF) | Initial bolus typically 10–20 mg IV (or roughly 1× home oral dose) | 5–10 mg/h continuous IV infusion, titrated to response (institutional protocols vary widely) | Up to 200 mg/day per FDA-label upper bound for HF | Not separately FDA-approved as continuous infusion but used clinically for refractory ADHF; mirrors the DOSE-trial framework for furosemide Bolus over 2 minutes; flush IV line with normal saline before and after administration (formulated above pH 8.3) |
| Older adults (≥ 65 y) | Standard starting doses | Cautious titration with attention to renal function | As above | Per FDA label, total plasma clearance and t½ remain unchanged in the elderly; renal clearance falls, but hepatic metabolism compensates. No specific age-based dose adjustment is recommended Orthostatic hypotension is no greater than with placebo in the FDA-cited HTN trials |
| Pediatric patients | Per FDA label, safety and effectiveness in pediatric patients have not been established. Off-label use is occasionally described in tertiary references but with limited supporting data | If used off-label, monitor closely for ototoxicity and electrolyte disturbance Premature infants are at theoretical risk of nephrocalcinosis/nephrolithiasis based on class effects per FDA label | ||
Conventional equivalency for loop diuretics: torsemide 10–20 mg ≈ furosemide 40 mg PO ≈ furosemide 20 mg IV ≈ bumetanide 1 mg per heart-failure guideline tables. Three pragmatic torsemide advantages: (1) bioavailability is approximately 80% with low inter-subject variation per the FDA label, so oral and IV doses are therapeutically equivalent and enable seamless route conversion; (2) duration of 6–8 h supports once-daily dosing in many patients, in contrast to twice-daily furosemide; (3) total plasma clearance and t½ remain unchanged in renal impairment and aging because hepatic metabolism compensates. The TRANSFORM-HF pragmatic trial showed no 12-month mortality difference between torsemide and furosemide after a heart-failure hospitalization, so the choice between agents now turns mainly on tolerability, cost, and absorption reliability.
Per the FDA label, torsemide injection is formulated above pH 8.3 — the IV line should be flushed with normal saline before and after administration to avoid pH-related precipitation. Continuous infusion stability has been demonstrated for 24 hours at room temperature in 5% dextrose, 0.9% sodium chloride, and 0.45% sodium chloride. Generic injection is supplied as 10 mg/mL in 2 mL and 5 mL single-dose vials. Note that branded Demadex injection was discontinued by Roche in 2008 — the FDA confirmed this discontinuation was not for safety or effectiveness reasons, and generic ANDAs remain available.
Pharmacology
Mechanism of Action
Torsemide is a pyridine-sulfonylurea loop diuretic — chemically distinct from the sulfonamide loop diuretics furosemide and bumetanide. Per the FDA label, micropuncture studies in animals have demonstrated that torsemide acts from within the lumen of the thick ascending limb of the loop of Henle, where it inhibits the Na⁺/K⁺/2Cl⁻ cotransporter (NKCC2). Clinical pharmacology studies have confirmed this site of action in humans, and effects in other nephron segments have not been demonstrated. Diuretic activity correlates better with the rate of drug excretion in the urine than with plasma concentration — a feature shared across the loop diuretic class.
Torsemide increases urinary excretion of sodium, chloride, and water without significantly altering glomerular filtration rate, renal plasma flow, or acid–base balance per the FDA label. In healthy subjects, the dose–response relationship for sodium excretion is linear over the range of 2.5 mg to 20 mg. The increase in potassium excretion is negligible after a single dose of up to 10 mg and only slight (5–15 mEq) after a 20 mg single dose — a more favorable kaliuretic profile than that of comparable doses of furosemide or bumetanide. The antihypertensive effect of torsemide is thought to involve both its diuretic action and a class-effect reduction in vascular resistance with chronic dosing.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Per FDA label, oral bioavailability is approximately 80% (90% CI 75–89%) with little inter-subject variation. Drug is absorbed with little first-pass metabolism. Cmax within 1 h after oral dosing; Cmax and AUC are dose-proportional from 2.5 mg to 200 mg. Food delays time-to-Cmax by about 30 minutes but overall AUC and diuretic activity are unchanged. Absorption is essentially unaffected by renal or hepatic dysfunction | The reproducibility of oral absorption — in contrast to furosemide tablets (~64% with high variability) — is the single most important pharmacokinetic advantage of torsemide. Patients can take it with meals for tolerability; gut wall edema in HF affects torsemide absorption far less than furosemide |
| Distribution | Per FDA label, volume of distribution is 12–15 L in healthy adults and in patients with mild-to-moderate renal failure or congestive heart failure. In hepatic cirrhosis, Vd is approximately doubled. Plasma protein binding exceeds 99% | The very high protein binding limits glomerular filtration of unbound drug — most renal clearance occurs through active tubular secretion via the organic anion transporter. The doubled Vd in cirrhosis partially explains why higher initial doses are sometimes required despite the lower hepatic clearance of cirrhotic patients |
| Metabolism | Per FDA label, torsemide is metabolised primarily by hepatic CYP2C9, with minor contributions from CYP2C8 and CYP2C18. Three main metabolites are identified in humans: M1 (methyl-hydroxylation product, some pharmacological activity), M3 (ring-hydroxylation product, some activity), and M5 (carboxylic-acid derivative formed by oxidation of M1, biologically inactive — the major metabolite). Hepatic metabolism accounts for approximately 80% of total clearance | The CYP2C9-mediated metabolism makes torsemide uniquely vulnerable among loop diuretics to interactions with CYP2C9 inhibitors (amiodarone, fluconazole, miconazole, oxandrolone) and inducers (rifampin). It also means torsemide may affect the disposition of CYP2C9 substrates with narrow therapeutic indices — particularly warfarin and phenytoin — by metabolic inhibition |
| Elimination | Per FDA label, t½ ≈ 3.5 h in healthy adults. Hepatic metabolism contributes ~80% of total clearance and renal excretion of unchanged drug ~20%. After a single oral dose, urinary recovery is: torsemide 21%, M1 12%, M3 2%, M5 34%. In renal failure, renal clearance falls but total clearance and t½ are preserved because hepatic metabolism remains intact. In hepatic cirrhosis, plasma t½ and renal clearance are both increased but total clearance is unchanged. Per FDA label, torsemide is not dialysable | The dual-route elimination is the central design feature of torsemide: each pathway compensates when the other is impaired, so dose adjustment in renal or hepatic disease is by clinical response rather than absolute reduction. In decompensated heart failure both pathways are reduced (~50% total clearance) due to hepatic congestion and reduced renal perfusion |
Side Effects
Torsemide has one of the more favorable safety profiles among loop diuretics, reflected in two notable observations from the FDA label: (1) discontinuation due to adverse reactions occurred in 3.5% of US patients on torsemide versus 4.4% on placebo — actually lower than placebo; and (2) at hypertensive doses (5–10 mg/day), the incidence of clinically significant hypokalemia (K < 3.5 mEq/L) was 1.5% with torsemide versus 3% with placebo. The most common drug-attributable adverse effect is excessive urination, predictably dose-related and dominant at higher doses. Most metabolic effects are class-typical of loop diuretics and are dose-dependent.
| Adverse Effect | Incidence (FDA PI) | Clinical Note |
|---|---|---|
| Excessive urination (HTN trial, 10 mg dose) | 15% at 10 mg vs 4% at 5 mg vs 1% on placebo per FDA PI | Dose-related; reflects predictable pharmacology rather than toxicity. In patients treated for cardiac, renal, or hepatic edema, excessive urination is generally not reported as an adverse event because it is therapeutic intent |
| Adverse Effect | Incidence (FDA PI) | Clinical Note |
|---|---|---|
| Excessive urination (overall, all indications) | 6.7% torsemide vs 2.2% placebo per FDA PI | The most common reported adverse reaction in placebo-controlled trials |
| Discontinuation due to adverse reactions | 3.5% torsemide vs 4.4% placebo per FDA PI | Notably lower than placebo — supports the favorable tolerability profile of standard doses |
| Hyperuricemia (asymptomatic) | Mean increase 1.2 mg/dL at 10 mg/day for 6 weeks per FDA PI | Per FDA label, gout may rarely be precipitated; check baseline uric acid in patients with gout history |
| Hyperglycemia | Mean increase 5.5 mg/dL at 10 mg/day for 6 weeks per FDA PI | Per FDA label, in long-term studies in diabetics, mean fasting glucose values were not significantly changed from baseline |
| BUN increase | Mean increase 1.8 mg/dL at 10 mg/day for 6 weeks per FDA PI | Reversible upon discontinuation; reflects volume contraction |
| System / Adverse Effect | Frequency | Clinical Note |
|---|---|---|
| Hypokalemia (K < 3.5 mEq/L) at HTN doses | 1.5% torsemide vs 3% placebo per FDA PI | Less hypokalemia than placebo at hypertensive doses. At higher doses used for HF, cirrhosis, and CKD edema, hypokalemia is more frequent and dose-related per FDA label |
| Gastrointestinal — pancreatitis, abdominal pain | Postmarketing | Hold drug if pancreatitis is suspected; obtain lipase and imaging |
| Nervous system — paresthesia, confusion, visual impairment, loss of appetite | Postmarketing | Confusion and paresthesia may signal hyponatremia or thiamine deficiency — check electrolytes and B1 status |
| Hematologic — leukopenia, thrombocytopenia, anemia | Postmarketing | Obtain CBC if symptoms suggestive (bleeding, pallor, infection) |
| Hepatobiliary — increase in liver transaminases, gamma-glutamyltransferase | Postmarketing | Check LFTs if persistent fatigue or new jaundice |
| Metabolism — thiamine (vitamin B₁) deficiency | Postmarketing | An underrecognized loop-diuretic effect; consider thiamine repletion in chronic HF on long-term high-dose therapy with malnutrition or alcohol use |
| Skin / hypersensitivity — Stevens–Johnson syndrome, toxic epidermal necrolysis, photosensitivity, pruritus | Postmarketing | Discontinue immediately for any blistering or mucosal involvement; hospital-level supportive care |
| Urogenital — acute urinary retention | Postmarketing | Particularly in older men with prostatic hypertrophy; counsel patients to seek care if unable to void |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Symptomatic dehydration, hypotension, worsening renal function | Particular risk in salt-depleted patients or those on RAAS inhibitors per FDA label | Days | Hold drug; assess volume; resume at lower dose; review concurrent ACEi/ARB/NSAID |
| Acute renal failure | Increased with concurrent NSAIDs, aminoglycosides, cisplatin, radiocontrast per FDA label | Days to weeks | Discontinue; correct volume; nephrology input if not resolving |
| Severe hyponatremia, hypokalemia, hypomagnesemia, hypocalcemia, hypochloremic alkalosis | Dose-related; more common at high doses in HF/cirrhosis/CKD per FDA label | Days to weeks | Hold drug, correct electrolytes; in QT-prolonging contexts maintain K⁺ > 4 mEq/L; pair with MRA pre-emptively |
| Hepatic encephalopathy (in cirrhosis) | Risk per FDA label especially with rapid diuresis | Hours to days | Suspend or discontinue per FDA label; reduce dose; pair with aldosterone antagonist; treat precipitants |
| Ototoxicity (tinnitus, usually reversible hearing loss) | Risk increased with high doses, severe renal impairment, hypoproteinemia, concurrent ototoxic agents per FDA label | Hours to days | Stop or slow infusion; switch to oral; arrange audiometry if symptoms persist |
| Seizures (very high doses in acute renal failure) | 19% at 520–1200 mg/day in an acute renal failure study (6/32 each torsemide and furosemide vs 1/32 placebo) per FDA PI | Hours after dosing | Limit doses; benzodiazepines for active seizures; reassess fluid/electrolyte balance |
| Stevens–Johnson syndrome / toxic epidermal necrolysis | Postmarketing reports per FDA label | Days to weeks | Discontinue immediately; hospital-level supportive care; never rechallenge |
| Pancreatitis | Postmarketing reports per FDA label | Variable | Discontinue if confirmed; supportive care |
One of the most striking observations in the FDA Demadex label is that the rate of hypokalemia (K < 3.5 mEq/L) at the HTN doses of 5–10 mg/day was actually lower with torsemide (1.5%) than with placebo (3%), and the mean potassium decrease at 6 weeks was only ~0.1 mEq/L. This contrasts with thiazide diuretics and with higher-dose loop diuretics. The clinical implication is that, at the licensed antihypertensive doses, routine prophylactic potassium supplementation is generally unnecessary — although periodic monitoring remains appropriate. At the higher doses required in HF, cirrhosis, and CKD edema, hypokalemia becomes more common and dose-related and warrants standard prevention strategies.
Drug Interactions
Torsemide’s interaction profile differs meaningfully from that of furosemide and bumetanide because of its hepatic CYP2C9 metabolism. In addition to the expected pharmacodynamic interactions (NSAIDs, RAAS inhibitors, lithium, ototoxic drugs), torsemide is uniquely subject to pharmacokinetic interactions with CYP2C9 inhibitors and inducers, and can in turn affect the disposition of CYP2C9 substrates with narrow therapeutic indices — particularly warfarin and phenytoin. Note also several reassuring “no interaction” findings from formal studies cited in the FDA label.
Monitoring
- Serum Electrolytes (K, Na, Cl, Mg, Ca) Baseline; periodically; more frequently in high-dose or prolonged therapyRoutine Per FDA label, monitor serum electrolytes and blood glucose periodically. Hypokalemia is dose-related: at HTN doses (5–10 mg) it is uncommon (1.5% K < 3.5 mEq/L per FDA PI, lower than placebo), but at higher doses for HF, cirrhosis, or CKD it is observed with greater frequency.
- Renal Function (BUN / creatinine / eGFR) Baseline; within 1–2 weeks of dose change; routinely thereafterRoutine Per FDA label, monitor volume status and renal function periodically. Excessive diuresis may cause symptomatic dehydration, hypotension, and worsening renal function — particular risk in salt-depleted patients, those on RAAS inhibitors, or those receiving concurrent nephrotoxic drugs (aminoglycosides, cisplatin, NSAIDs).
- Daily Body Weight (in HF / cirrhosis) Daily during dose titration and acute decongestionRoutine Aim for ~0.5–1 kg/day net negative balance during acute HF decongestion; in cirrhotic patients without peripheral edema, do not exceed ~0.5 kg/day to avoid intravascular volume contraction with AKI or encephalopathy.
- Blood Pressure At each visit; orthostatic measurements in symptomatic patientsRoutine Per FDA label, antihypertensive effect approaches maximum at 4–6 weeks and may continue increasing for up to 12 weeks. There is no significant orthostatic effect at HTN doses, but combination with RAAS inhibitors increases hypotension risk.
- Glucose and Uric Acid Baseline; periodically — particularly in diabetes or gout historyTrigger-based Per FDA label, mean glucose increase 5.5 mg/dL and mean uric acid increase 1.2 mg/dL at 10 mg/day for 6 weeks. In long-term diabetic studies, mean fasting glucose was unchanged from baseline. Asymptomatic hyperuricemia is common; gout may rarely be precipitated.
- INR / Anticoagulation Effect (if on warfarin) After starting or stopping torsemide; with any dose changeTrigger-based Per FDA label, torsemide may affect efficacy and safety of CYP2C9 substrates with narrow therapeutic range, including warfarin. Note that protein binding is unaffected.
- Lithium Levels (if on lithium) Within 5–7 days of starting or stopping torsemide; routinely thereafterTrigger-based Per FDA label, torsemide reduces renal clearance of lithium with high risk of lithium toxicity; monitor lithium levels periodically when co-administered.
- Hearing / Audiometry If high-dose IV, severe renal impairment, or concurrent ototoxic agents; symptoms of tinnitus or hearing changeTrigger-based Per FDA label, higher than recommended doses, severe renal impairment, and hypoproteinemia increase ototoxicity risk. Hearing changes are usually reversible.
- Liver Function and Mental Status (in cirrhosis) Baseline and during dose changes; alert for behavioural changeTrigger-based Per FDA label, sudden alterations in fluid and electrolyte balance can precipitate hepatic coma in cirrhosis with ascites; consider suspending or discontinuing torsemide if encephalopathy develops.
- CBC / LFTs Baseline; whenever clinically suspiciousTrigger-based Postmarketing reports per FDA label include leukopenia, thrombocytopenia, anemia, and elevated transaminases / GGT. Obtain labs if suggestive symptoms.
Contraindications & Cautions
Absolute Contraindications
- Anuria — per FDA label; torsemide requires functioning tubular secretion to act
- Hepatic coma — per FDA label
- Hypersensitivity to torsemide — per FDA label
- Hypersensitivity to povidone — per FDA label, a unique torsemide contraindication; the Demadex tablet contains povidone USP as an excipient (a feature not present in furosemide or bumetanide labelling)
Relative Contraindications (Specialist Input Recommended)
- Decompensated cirrhosis with prior hepatic encephalopathy — per FDA label, initiate diuresis in hospital and pair with aldosterone antagonist or potassium-sparing diuretic
- Severe hyponatremia or hypokalemia not yet corrected — defer initiation or up-titration until electrolytes are repleted
- Concurrent lithium therapy — combination is permissible only with close lithium monitoring
- Severe hypoproteinemia — per FDA label, increases ototoxicity risk
- Patients under 18 years of age — per FDA label, safety and efficacy in pediatric patients have not been established
Use with Caution
- Concurrent RAAS inhibitors — per FDA label, increased risk of hypotension and renal impairment, particularly in salt-depleted patients
- Concurrent NSAIDs — per FDA label, associated with acute renal failure; reduces diuretic and antihypertensive effects
- Diabetes mellitus — small mean increase in serum glucose at HTN doses per FDA label; long-term effect is minimal
- Gout / hyperuricemia — small mean increase in uric acid at HTN doses per FDA label; rarely precipitates clinical gout
- Pregnancy — per FDA label, no human data; use only when benefit outweighs risk
- Lactation — per FDA label, no human-milk data; diuretics may suppress lactation
- Concurrent CYP2C9 inhibitors / inducers — per FDA label, monitor diuretic effect and adjust dose if necessary
- Concurrent aminoglycosides — additive ototoxicity, especially in renal impairment; per FDA label, avoid if possible
Unlike furosemide and bumetanide, torsemide does not carry an FDA boxed warning. The Warnings/Precautions section identifies three principal risks: (1) Hypotension and worsening renal function — excessive diuresis may cause symptomatic dehydration, blood-volume reduction, and AKI, particularly in salt-depleted patients or those on RAAS inhibitors; (2) Electrolyte and metabolic abnormalities — torsemide can cause hypokalemia, hyponatremia, hypomagnesemia, hypocalcemia, hypochloremic alkalosis, hyperglycemia, and asymptomatic hyperuricemia; and (3) Ototoxicity — usually reversible tinnitus or hearing loss, with greater risk at higher doses, in severe renal impairment, with hypoproteinemia, and with concurrent ototoxic agents. Standard monitoring of volume status, electrolytes, and renal function addresses all three risks.
Patient Counselling
Purpose of Therapy
Torsemide is a “water tablet” that helps the kidneys remove extra fluid and salt from the body. For people with heart failure, cirrhosis, or kidney disease, this reduces breathlessness, leg swelling, and abdominal bloating, and can help prevent admissions to hospital. It is also used to treat high blood pressure. The medicine starts to work within an hour of an oral dose and lasts about 6 to 8 hours, so most people take it once a day.
How to Take
Take the dose in the morning to avoid being woken at night by the need to urinate. Torsemide can be taken with or without food — taking it with food may delay the start of the effect by about half an hour but does not change how well it works overall. Do not stop the medicine suddenly without speaking to the prescriber, especially if it is being used for heart failure where rebound fluid retention can occur. If a dose is missed, take it as soon as remembered unless it is close to the next scheduled dose; never double up. Keep a daily weight log on the same scale at the same time each morning — a sustained gain or loss of more than 1–2 kg over a few days is a useful trigger for contacting the clinic.
Sources & References
- Meda Pharmaceuticals Inc. DEMADEX® (torsemide) tablets, for oral use — Prescribing Information. Reference ID: 4051083. Revised February 2017. accessdata.fda.gov/drugsatfda_docs/label/2017/020136s027lbl.pdfCurrent FDA-approved label for Demadex tablets — primary source for indications (HF/renal/hepatic edema and hypertension), dosing, pharmacokinetics, adverse-reaction incidence rates, drug interactions, and contraindications including the unique povidone hypersensitivity contraindication.
- FDA. Torsemide Injection 10 mg/mL — Prescribing Information. DailyMed setid cf288ad5-d4e7-4b0b-bfd0-41c5327e6984. dailymed.nlm.nih.govReference label for the parenteral formulation; primary source for IV bolus and continuous-infusion guidance, IV compatibility, and pH-related precipitation precautions.
- Sarfez Pharmaceuticals Inc. SOAANZ® (torsemide) tablets — Prescribing Information. FDA approved June 2021. accessdata.fda.gov/drugsatfda_docs/label/2021/213218s000lbl.pdfFDA-approved label for the extended-release torsemide formulation. Indicated for edema associated with heart failure or renal disease only — narrower than the standard Demadex/generic indication set, and not approved for hepatic edema or hypertension.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063Class 1, Level B-NR recommendation for loop diuretics — including torsemide — as first-line therapy in HF patients with congestion; source for the loop-diuretic equivalency table.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065Modern hypertension guidance; loop diuretics including torsemide are useful particularly when reduced eGFR limits thiazide effectiveness.
- Mentz RJ, Anstrom KJ, Eisenstein EL, et al; TRANSFORM-HF Investigators. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure. JAMA. 2023;329(3):214-223. doi:10.1001/jama.2022.23924The most important contemporary head-to-head pragmatic trial of torsemide vs furosemide; demonstrated no difference in 12-month all-cause mortality, fundamentally reframing the choice between loop diuretics.
- Greene SJ, Velazquez EJ, Anstrom KJ, et al; TRANSFORM-HF Investigators. Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial. JACC Heart Fail. 2021;9(5):325-335. doi:10.1016/j.jchf.2021.01.013 · PMID 33714745Methodological companion to TRANSFORM-HF — useful context for interpreting the trial’s pragmatic design.
- Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure (DOSE trial). N Engl J Med. 2011;364(9):797-805. doi:10.1056/NEJMoa1005419Framework for choosing low-dose vs high-dose and bolus vs continuous-infusion strategies for IV loop diuretics in ADHF — applicable to torsemide as well as furosemide.
- Brater DC. Diuretic therapy. N Engl J Med. 1998;339(6):387-395. doi:10.1056/NEJM199808063390607Authoritative review of diuretic pharmacology, including comparative torsemide handling vs furosemide and bumetanide; foundational reference for understanding the dual hepatic–renal elimination of torsemide.
- Ellison DH, Felker GM. Diuretic Treatment in Heart Failure. N Engl J Med. 2017;377(20):1964-1975. doi:10.1056/NEJMra1703100Contemporary review of diuretic treatment in HF — practical reference for diuretic resistance, sequential nephron blockade, and continuous-infusion strategies.
- Wargo KA, Banta WM. A comprehensive review of the loop diuretics: should furosemide be first line? Ann Pharmacother. 2009;43(11):1836-1847. doi:10.1345/aph.1M177 · PMID 19843838Modern comparative review of loop-diuretic pharmacokinetics, efficacy, and cost — frames the case for torsemide as a reasonable alternative to furosemide based on its more reliable bioavailability.
- Huxel C, Raja A, Ollivierre-Lawrence MD. Loop Diuretics. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; updated 2023. PMID: 31536262Background reference on loop-diuretic pharmacology and equivalency tables.